Indinavir (Crixivan)

Indinavir (Crixivan) is an anti-HIV drug that reduces the amount of virus in the body. Anti-HIV drugs such as indinavir slow down or prevent damage to the immune system, and reduce the risk of developing AIDS-related illnesses .

Indinavir is a protease inhibitor. Protease is the enzyme that HIV uses to break up large viral proteins so new HIV particles can be made. For more information about how protease inhibitors work, see Protease inhibitors.

Indinavir was previously known by the codenames MK-639 and L-735,524. It is manufactured by Merck Sharp & Dohme Ltd., who market the drug as Crixivan. Several generic versions of indinavir are manufactured by Indian companies, including Indivir (Cipla), Indivex (Aurobindo), Virodin (Ranbaxy) and Indivir (Genixpharma).

In March 1996, indinavir was approved for use in the United States. In October 1996, it was approved throughout the European Union for use in combination with nucleoside reverse transcriptase inhibitors (NRTIs) for treating HIV-positive adults with advanced or progressive immunodeficiency.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap